ArticleCancers2023

The Defined TLR3 Agonist, Nexavant, Exhibits Anti-Cancer Efficacy and Potentiates Anti-PD-1 Antibody Therapy by Enhancing Immune Cell Infiltration.

Seung-Hwan Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.